REFERENCES
- Malfertheiner P, Megarud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007; 56 (6): 772–81.
- Chey WD, Wong BC. Practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol 2007; 102 (8): 1808–25.
- Vakil N. Helicobacter pylori treatment: new wine in old bottles? Am J Gastroenterol 2009; 104 (1): 26–30.
- Megraud F. Helicobacter pylori antibiotic resistance, prevalence, importance and advance in testing. Gut 2004; 53: 1374–84.
- Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gas-trenterol Hepatol 2008; 5 (6): 321–31.
- Tonkic M, Tonkic A, Goi -Bargi I, Juki I, Simuni M, Punda-Poli V. Primary resistance and antibiotic minimum in-hibitory concentrations for Helicobacter pylori strains in Split, Croatia. J Chemother 2006; 18 (4): 437-39.
- Tonkic A, Tonkic M, Goi -Bargi I, Juki I, Mfge S. Anti-botic resistance of Helicobacter pylori isolated in Split, Southern Croatia. Int J Antimicrob Agents 2005; 25: 449–50.
- Koivisto TT, Rautelin HI, Voutilainen ME, Niemelä SE, Heikkinen M, Sipponen PI et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in Finnish popula-tion. Aliment Pharmacol Ther 2004; 9: 1009–17.
- Petersen AM, Gjode P, Vinge OD, Jensen S, Krogfelt KA. Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998-2004: no need for concern? Helicobacter 2006; 1: 210-1.
- Duck WM, Sobel J, Pruckler JM. Antimicrobial resistance, incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10 (6): 1088–94.
- Goossens H, Ferech M, Van der Stichele R, Elseviers M; ESAC Project Group. Outpatient antbiotic use in Europe and association with resistance a cross-rational database study. Lancet 2005; 365: 579–87.